Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatostatin for Early Postoperative Simple Small Bowel Obstruction
NCT01082627Phase 4Completed
- Sponsor
- General Hospital of Eastern Military Command
- Start
- Jun 2009
- Primary completion
- Nov 2010
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of somatostatin in small bowel obstruction (SBO) (2 arms), sponsored by General Hospital of Eastern Military Command. Primary endpoint: Complete recovery rate of EPSSBO at 14 days. Started Jun 2009; status: completed.
02
Drugs
somatostatin
03
Conditions
small bowel obstruction (SBO)
Beyond the preview
Go deeper on NCT01082627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01082627.